Unknown

Dataset Information

0

Design and Development of Highly Potent HIV-1 Protease Inhibitors with a Crown-Like Oxotricyclic Core as the P2-Ligand To Combat Multidrug-Resistant HIV Variants.


ABSTRACT: Design, synthesis, and evaluation of a new class of exceptionally potent HIV-1 protease inhibitors are reported. Inhibitor 5 displayed superior antiviral activity and drug-resistance profiles. In fact, this inhibitor showed several orders of magnitude improved antiviral activity over the FDA approved drug darunavir. This inhibitor incorporates an unprecedented 6-5-5 ring-fused crown-like tetrahydropyranofuran as the P2 ligand and an aminobenzothiazole as the P2' ligand with the (R)-hydroxyethylsulfonamide isostere. The crown-like P2 ligand for this inhibitor has been synthesized efficiently in an optically active form using a chiral Diels-Alder catalyst providing a key intermediate in high enantiomeric purity. Two high resolution X-ray structures of inhibitor-bound HIV-1 protease revealed extensive interactions with the backbone atoms of HIV-1 protease and provided molecular insight into the binding properties of these new inhibitors.

SUBMITTER: Ghosh AK 

PROVIDER: S-EPMC5605781 | biostudies-literature | 2017 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Design and Development of Highly Potent HIV-1 Protease Inhibitors with a Crown-Like Oxotricyclic Core as the P2-Ligand To Combat Multidrug-Resistant HIV Variants.

Ghosh Arun K AK   Rao Kalapala Venkateswara KV   Nyalapatla Prasanth R PR   Osswald Heather L HL   Martyr Cuthbert D CD   Aoki Manabu M   Hayashi Hironori H   Agniswamy Johnson J   Wang Yuan-Fang YF   Bulut Haydar H   Das Debananda D   Weber Irene T IT   Mitsuya Hiroaki H  

Journal of medicinal chemistry 20170418 10


Design, synthesis, and evaluation of a new class of exceptionally potent HIV-1 protease inhibitors are reported. Inhibitor 5 displayed superior antiviral activity and drug-resistance profiles. In fact, this inhibitor showed several orders of magnitude improved antiviral activity over the FDA approved drug darunavir. This inhibitor incorporates an unprecedented 6-5-5 ring-fused crown-like tetrahydropyranofuran as the P2 ligand and an aminobenzothiazole as the P2' ligand with the (R)-hydroxyethyls  ...[more]

Similar Datasets

| S-EPMC3800042 | biostudies-literature
| S-EPMC5613016 | biostudies-literature
| S-EPMC6658756 | biostudies-literature
| S-EPMC4133278 | biostudies-literature
| S-EPMC6711809 | biostudies-literature
| S-EPMC2797486 | biostudies-literature
| S-EPMC7425579 | biostudies-literature
| S-EPMC7549267 | biostudies-literature
| S-EPMC5912973 | biostudies-literature
| S-EPMC3719844 | biostudies-literature